Stockscreener 앱 받기
1.46
5.04%
0.07
시간 외 거래:
1.48
0.02
+1.37%
전일 마감가:
$1.39
열려 있는:
$1.48
하루 거래량:
2.73M
Relative Volume:
1.00
시가총액:
$412.89M
수익:
$53.43M
순이익/손실:
$-52.49M
주가수익비율:
-4.068
EPS:
-0.3589
순현금흐름:
$-58.29M
1주 성능:
+7.35%
1개월 성능:
+12.31%
6개월 성능:
-5.19%
1년 성능:
+176.20%
1일 변동 폭
$1.435
$1.545
1주일 범위
$1.3663
$1.575
52주 변동 폭
$0.483
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
명칭
Invivyd Inc
전화
(781) 819-0080
주소
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.46 | 393.10M | 53.43M | -52.49M | -58.29M | -0.3589 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-22 | 개시 | BTIG Research | Buy |
| 2025-11-25 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2025-10-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-26 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | 개시 | H.C. Wainwright | Buy |
모두보기
Invivyd Inc 주식(IVVD)의 최신 뉴스
Invivyd gives 17 new hires options to buy 731,000 shares - Stock Titan
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Invivyd appoints Michael Mina as chief medical officer By Investing.com - Investing.com India
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances - Investing.com
Invivyd Ends King & Spalding Lobbying Engagement After Three Weeks - Legis1
Invivyd (IVVD) price target increased by 25.00% to 10.20 - MSN
Invivyd (IVVD) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
IVVD Price Today: Invivyd, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Invivyd rises after update from late-stage trial for COVID therapy - MSN
Biotech Biz Moves Into Ex-Bank Site - New Haven Independent
Invivyd Shareholder Action Reminder - TMX Newsfile
Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Invivyd, Inc. draws on 73 years of DNA innovation to guide viral research - Traders Union
Invivyd (IVVD) Announces Favorable Phase 3 Analysis for VYD2311 COVID-19 Treatment - Yahoo Finance
10 Best NASDAQ Growth Stocks to Buy and Hold Forever - Insider Monkey
Is Invivyd (IVVD) stock overvalued today | Invivyd Inc posts narrower loss, EPS beats estimates by 55.2%Analyst Ratings - Cổng thông tin điện tử tỉnh Lào Cai
Invivyd Inc posts narrower loss, EPS beats estimates by 55.2%Real Time Stock Idea Network - Xã Châu Thành
Invivyd Inc stock (US46186M1080): Is its monoclonal antibody strategy strong enough for COVID market - AD HOC NEWS
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit - The Manila Times
Invivyd chair joins Mehmet Oz, Mark Cuban at POLITICO health event - Stock Titan
Invivyd Inc stock (US46186M1080): Is its monoclonal antibody edge strong enough for COVID market rec - AD HOC NEWS
Invivyd stock surges as FDA alignment boosts COVID-19 program - MSN
Aug Reactions: What are Invivyd Incs technical support levelsLayoff News & Expert-Curated Trade Recommendations - baoquankhu1.vn
Invivyd: Why The Trial Upsizing Isn't The Green Light Bulls Think It Is (NASDAQ:IVVD) - Seeking Alpha
Authentic virus research in labs faces adaptation hurdles, Invivyd, Inc. asserts - Traders Union
Invivyd unveils measles monoclonal antibody candidate VMS-063 - BioWorld News
H.C. Wainwright reiterates Invivyd stock rating on measles program By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Invivyd stock rating on measles program - Investing.com
Invivyd upsizes COVID-19 trial, targets measles antibody By Investing.com - Investing.com Australia
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody CandidateSlideshow (NASDAQ:IVVD) 2026-04-09 - Seeking Alpha
Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063 - MarketBeat
Invivyd stock surges 25% on COVID-19 trial progress By Investing.com - Investing.com Australia
Invivyd reveals plans to test an antibody drug against measles - BioPharma Dive
Invivyd posts update from late-stage COVID trial (IVVD:NASDAQ) - Seeking Alpha
Invivyd stock surges 25% on COVID-19 trial progress - Investing.com
Invivyd Inc (IVVD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):